MedPath

Itraconazole

Generic Name
Itraconazole
Brand Names
Sporanox, Tolsura
Drug Type
Small Molecule
Chemical Formula
C35H38Cl2N8O4
CAS Number
84625-61-6
Unique Ingredient Identifier
304NUG5GF4
Background

One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions
Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2024-12-09
Last Posted Date
2025-01-28
Lead Sponsor
AbbVie
Target Recruit Count
12
Registration Number
NCT06722430
Locations
🇺🇸

Acpru /Id# 271617, Grayslake, Illinois, United States

A Study of the Effect of Itraconazole and Phenytoin on MK-1084 in Healthy Adults (MK-1084-008)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT06719557
Locations
🇺🇸

Celerion (Site 0001), Lincoln, Nebraska, United States

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Phase 1
Recruiting
Conditions
Advanced Breast Cancer
Interventions
First Posted Date
2024-12-02
Last Posted Date
2025-03-28
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
32
Registration Number
NCT06710990
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-11-27
Last Posted Date
2025-03-25
Lead Sponsor
Pfizer
Target Recruit Count
26
Registration Number
NCT06706869
Locations
🇺🇸

Research Centers of America ( Hollywood ), Hollywood, Florida, United States

🇺🇸

Research Centers of America, Hollywood, Florida, United States

Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults

Phase 1
Not yet recruiting
Conditions
Rifampicin-Resistant Pulmonary Tuberculosis Patients
Interventions
First Posted Date
2024-11-22
Last Posted Date
2025-02-12
Lead Sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Target Recruit Count
16
Registration Number
NCT06701136

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

Phase 1
Recruiting
Conditions
Healthy Volunteer
Interventions
First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
AbbVie
Target Recruit Count
112
Registration Number
NCT06698926
Locations
🇺🇸

Acpru /Id# 270532, Grayslake, Illinois, United States

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2024-11-15
Last Posted Date
2025-04-15
Lead Sponsor
Genentech, Inc.
Target Recruit Count
18
Registration Number
NCT06690138
Locations
🇺🇸

Dallas Clinical Research Unit, Dallas, Texas, United States

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-11-14
Last Posted Date
2024-11-14
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT06688045
Locations
🇺🇸

Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2024-11-07
Last Posted Date
2025-05-11
Lead Sponsor
Immunome, Inc.
Target Recruit Count
22
Registration Number
NCT06677996
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Phase 1
Active, not recruiting
Conditions
Healthy Volunteer
Interventions
First Posted Date
2024-11-04
Last Posted Date
2025-02-03
Lead Sponsor
Aligos Therapeutics
Target Recruit Count
24
Registration Number
NCT06672900
Locations
🇺🇸

PPD Austin Research Unit, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath